U.S. markets open in 3 hours 42 minutes
  • S&P Futures

    4,559.25
    -6.00 (-0.13%)
     
  • Dow Futures

    35,599.00
    -45.00 (-0.13%)
     
  • Nasdaq Futures

    15,530.50
    -14.50 (-0.09%)
     
  • Russell 2000 Futures

    2,279.60
    -14.30 (-0.62%)
     
  • Crude Oil

    83.17
    -1.48 (-1.75%)
     
  • Gold

    1,787.40
    -6.00 (-0.33%)
     
  • Silver

    24.00
    -0.09 (-0.37%)
     
  • EUR/USD

    1.1596
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.6190
    0.0000 (0.00%)
     
  • Vix

    16.12
    +0.88 (+5.77%)
     
  • GBP/USD

    1.3738
    -0.0026 (-0.19%)
     
  • USD/JPY

    113.6070
    -0.5220 (-0.46%)
     
  • BTC-USD

    58,987.03
    -3,692.87 (-5.89%)
     
  • CMC Crypto 200

    1,417.21
    -87.94 (-5.84%)
     
  • FTSE 100

    7,255.09
    -22.53 (-0.31%)
     
  • Nikkei 225

    29,098.24
    -7.77 (-0.03%)
     

OCGN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ocugen, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - August 16, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and certain of its directors on behalf of shareholders who purchased or otherwise acquired Ocugen securities between February 2, 2021 and June 10, 2021 (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ocgn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the information submitted to the FDA was insufficient to support an EUA, (2) Ocugen would not file an Emergency Use Authorization with the FDA, (3) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/ocgn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Ocugen you have until August 17, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92330